AstraZeneca Pharma India has received a show cause notice from the National Pharmaceutical Pricing Authority (NPPA) for allegedly overcharging on its Symbicort Turbuhaler Inhalation Powder (60 doses).

In the notice dated September 11, 2025, the NPPA alleged the company marketed or manufactured the product at prices above the notified ceiling between April 2016 and July 2025.

The company, in its exchange filing, said the authority has asked for a response within 30 days.

The regulator has estimated the alleged overcharge at INR 60.49 crore plus interest. AstraZeneca, however, said the overall financial implication cannot be determined at this stage and disputed the quantum cited in the notice.

The notice comes weeks after the company announced an INR 176-crore investment to expand the capabilities and infrastructure at its Global Innovation & Technology Centre (GITC) in Chennai, its third such investment in India in the past two years. The centre serves as a hub for IT, Global Business Services, and supply chain strategy, supporting AstraZeneca’s global operations.